Successful treatment of anal and perianal condyloma acuminata with imiquimod.

Condyloma acuminata are genital or perianal warts caused mainly by human papillomavirus (HPV) types 6 and 11. In HIV-positive patients and in men who have sex with men (MSM), the prevalence of anal HPV infection is particularly high (45-95%) (1). Current therapies for condylorna acuminata include surgical excision and ablation by cryotherapy, electrocautery, or lasers. Imiquimod, a topical immune-response modifier, is also effective against condyloma acuminata and skin tumours, such as basal cell carcinoma and actinic keratosis (2). However, it is not practical to apply this cream topically to the mucous membranes ofthe anal canal, particularly inside the dentate line. Imiquimod has therefore been applied via suppositories (anal tampons) to anal canal condylomas (3). We report here a recurrent case of perianal and anal condyloma acuminata that was treated successfully with topical imiquimod to the perianal area. This report supports the widely held belief that imiquimod can induce a field effect in an area, such that susceptible lesions adjacent to the treated area can also be eradicated.

[1]  D. Hahnloser,et al.  What should we do about anal condyloma and anal intraepithelial neoplasia? Results of a survey , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[2]  V. Levine,et al.  Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism , 2011, The British journal of dermatology.

[3]  D. Czarnecki,et al.  Imiquimod treatment associated with a reduction in new skin cancer formation , 2009, Clinical and experimental dermatology.

[4]  Thomas A Luger,et al.  Immune response modifiers – mode of action , 2006, Experimental dermatology.

[5]  J. Langtry,et al.  Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas , 2006, Clinical and experimental dermatology.

[6]  R. Dummer,et al.  Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. , 2004, Archives of dermatology.

[7]  R. Gutzmer,et al.  Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma , 2002, The British journal of dermatology.

[8]  S. Akira,et al.  Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets , 2002, The Journal of experimental medicine.

[9]  R. Miller,et al.  Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. , 2000, The Journal of investigative dermatology.

[10]  M. Stanley,et al.  A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. , 1998, The Journal of infectious diseases.